Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUNET: 177Lu-DOTATATE in GEP-NET
NCT02489604Phase 2Terminated
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Dec 2013
- Primary completion
- Jan 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium Lu 177 dotatate in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Started Dec 2013; status: terminated.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT02489604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02489604.